Persistence with long-term PCSK9 inhibitors treatment and its effectiveness in Familial Hypercholesterolemia: data from the SAFEHEART study.

Rodrigo AlonsoRaquel Arroyo-OlivaresOvidio Muñiz-GrijalvoD Jose Luis Díaz-DíazJuan Sanchez Muñoz-TorreroManuel J RomeroRaimundo de AndrésDaniel ZambónMaría Dolores MañasFrancisco Fuentes-JimenezRocío AguadoPilar Alvarez-BañosFrancisco ArrietaPablo Gonzalez-BustosJosé CepedaMercedes Martin-OrdialesDaniel MosqueraAlfredo MichanLeopoldo Perez de IslaRosa ArguesoPedro Mata

Published in: European journal of preventive cardiology (2022)

Long-term persistence with PCSK9i in FH patients is very high, with a good QoL. Effectiveness in LDL-C reduction and LDL-C goal achievement dramatically improved with PCSK9i in this high-risk population in clinical practice setting.

Keyphrases

low density lipoprotein
clinical practice
end stage renal disease
randomized controlled trial
systematic review
newly diagnosed
ejection fraction
chronic kidney disease
electronic health record
big data
patient reported outcomes
artificial intelligence
combination therapy
data analysis